Transmucular Quadratus Lumborum Block: Potential Quadriceps Muscle Weakness

Summary

The aim of this study is to examine whether the administration of the TQL block cause motor block of the lumbar plexus and thereby quadriceps muscle weakness. The investigators hypothesise that the administration of a unilateral TQL block does not cause quadriceps muscle weakness compared to a placebo block.

Conditions

• Neuromuscular Blockade

Interventions

DRUG

Ropivacaine

30 mL Ropivacaine 0,75% administered as a unilateral TQL block

OTHER

Quadriceps muscle strength

Quadriceps muscle strength is assessed using a hand-held dynamometer. Each participant is tested pre block administration and 60 minutes after

OTHER

Timed Up and Go

To test mobilisation the standardised Timed Up and Go test is used. Each participant is tested pre block administration and 60 minutes after

OTHER

Single-leg 6 meter timed hop test

To test muscle strength and power the single-leg 6 meter jump test is used. Each participant is tested pre block administration and 60 minutes after

OTHER

Temperature discrimination

Dermatomal evaluation of cold and warm discrimination of the thoracic and lumbar dermatomes Approximately 60 minutes after block administration

OTHER

Pinprick test

Dermatomal evaluation of pinprick/sharp sensation of the thoracic and lumbar dermatomes. Approximately 60 minutes after block administration

DIAGNOSTIC_TEST

Blood samples

As a substudy the maximum serum concentration of ropivacaine is analyzed. Blood samples are taken at 0, 15, 30, 45 and 60 minutes after block administration

DIAGNOSTIC_TEST

Non-invasive blood pressure measurement

Non-invasive blood pressure is measured prior to block administration and 30 minutes after block administration

Sponsors & Collaborators

• Zealand University Hospital

  lead OTHER

Principal Investigators

• Katrine Tanggaard, MD · Zealand University Hospital, Department of Anaesthesiology

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2021-10-02

Primary Completion

2021-11-28

Completion

2021-11-28

Countries

• Denmark

Study Locations